Studies have shown that genetic or pharmacologic blockade SCD1 enhances sensitivity to ferroptosis in ovarian cancer and SREBP1 protects cells from ferroptosis through SCD1 activity [40, 41]. Here, SREBF1 is linked to ovarian cancer.